GTD

GTD - Getting Things Done, the productivity system by David Allen.

Here are the core concepts:

5 Steps of GTD:

Capture - Get everything out of your head into a trusted system (inbox)
Clarify - Process each item: is it actionable? What's the next action?
Organize - Sort into lists (projects, next actions, waiting for, someday/maybe, calendar)
Reflect - Weekly review to keep the system current and trusted
Engage - Do the work with confidence, knowing your system is complete

Key Lists:

Next Actions - concrete physical actions, organized by context (@home, @computer, @errands)
Projects - any outcome requiring more than one action step
Waiting For - delegated items you're tracking
Someday/Maybe - ideas you want to revisit but aren't committing to now
Calendar - only hard landscape (time-specific or day-specific items)

The 2-Minute Rule: If something takes less than 2 minutes, do it immediately when you process it.

The Weekly Review: Every week, clear inboxes, review all lists, update projects, and confirm your system reflects reality. This is what keeps GTD working long-term.

Core Insight: Your brain is for having ideas, not holding them. When everything is captured in a trusted external system, your mind is free to focus.

Is there a specific part of GTD you want to go deeper on - implementation, tools, troubleshooting a stalled system, or something else?

Managment of Diabetes in pregnancy

Reading File

Finding Sources

Searching PubMed

"diabetes in pregnancy" AND management

Reading File

I now have rich content from multiple authoritative sources. Let me compile the comprehensive answer.

Management of Diabetes in Pregnancy

Diabetes complicating pregnancy falls into two categories: pregestational diabetes mellitus (pgDM) - existing type 1 (T1DM) or type 2 (T2DM) - and gestational diabetes mellitus (GDM), which is glucose intolerance first identified during pregnancy.

1. Classification

Type	Features
T1DM in pregnancy	Autoimmune; insulin-deficient; most complex management
T2DM in pregnancy	Insulin-resistant; increasing in prevalence with obesity
GDM	Onset in pregnancy; resolves postpartum in most; recurs in ~50% of future pregnancies

2. Pathophysiology

Normal pregnancy causes a 50-60% decrease in insulin sensitivity by the third trimester, driven by placental hormones (human placental lactogen, progesterone, cortisol). Women who develop GDM have a pre-existing beta-cell dysfunction - their insulin secretory response cannot compensate for this physiologic resistance. Women with T1DM show a similar ~50% decrease in insulin sensitivity by late gestation, with variable decreases (even a dip) in early pregnancy around 9-16 weeks. - Creasy & Resnik's Maternal-Fetal Medicine, p. 1429

In T1DM, average insulin dose requirements follow a predictable pattern:

Early pregnancy (9-16 wks): may decrease
16-37 weeks: greatest increase
Near term: plateau or slight decline

3. Preconception Counseling (pgDM)

Target HbA1c < 6% before conception to minimize the risk of congenital malformations (especially cardiac and neural tube defects)
Screen and optimize management of end-organ complications: retinopathy, nephropathy, neuropathy, cardiovascular disease
Switch to insulin before conception; oral agents should generally be discontinued
Folic acid supplementation (5 mg/day in diabetics)
This is a cost-effective, evidence-based intervention - Harrison's 22nd Edition

4. Blood Glucose Targets During Pregnancy

Parameter	Target
Fasting	< 95 mg/dL (5.3 mmol/L)
1-hour postprandial	< 140 mg/dL (7.8 mmol/L)
2-hour postprandial	< 120 mg/dL (6.7 mmol/L)

Note: HbA1c is of limited utility for monitoring during pregnancy due to increased red cell turnover, which produces falsely low values. Home blood glucose monitoring (fasting + 1-2 hours after each meal) and continuous glucose monitoring (CGM) are preferred. - Harrison's 22nd Edition

5. Insulin Management

Dosing in pgDM

1st trimester: 0.7-0.8 units/kg/day
2nd trimester: 0.8-1.0 units/kg/day
3rd trimester: 0.9-1.2 units/kg/day

Regimens typically use basal-bolus insulin (long-acting + rapid-acting at meals), or continuation of a pre-pregnancy insulin pump (CSII) in appropriate patients.

Insulin in GDM

Insulin is the preferred pharmacologic therapy when dietary measures fail. It does not cross the placenta and has the strongest safety profile.

Oral Agents (GDM only)

Metformin: Associated with lower birth weights, less gestational weight gain, and lower preeclampsia rates vs. glyburide and insulin. However, it crosses the placenta - long-term effects on the child (including higher adiposity in some studies) remain uncertain.
Glyburide: Crosses the placenta; associated with higher rates of neonatal hypoglycemia and macrosomia compared to insulin - increasingly disfavored.
Both are alternatives when a patient declines or cannot reliably take insulin. - Harrison's 22nd Edition

Recent evidence (2024): A systematic review and meta-analysis (PMID: 37877940) confirmed insulin detemir is comparable in safety and efficacy to NPH insulin in pregnancy and is a reasonable long-acting option.

6. GDM - Step-by-Step Management

Step 1: Medical Nutrition Therapy (MNT)

Carbohydrate-controlled diet (complex carbs, not elimination)
~1800-2200 calories/day (not severe caloric restriction)
Distribute carbohydrates across 3 meals and 2-3 snacks
Caloric distribution aims for 33-40% carbohydrates, 35-40% fat, 20% protein

Step 2: Exercise

Brisk walking 20-30 minutes, 3x per week
Reduces postprandial glucose peaks

Step 3: Self-Monitoring of Blood Glucose (SMBG)

Fasting morning reading + 1-hour readings after each meal (4 readings/day minimum)

Step 4: Pharmacotherapy if targets not met

Insulin (preferred), or metformin/glyburide as alternatives

7. Fetal Surveillance

Situation	Surveillance Plan
GDM controlled by diet only, no complications	Delivery by 39 weeks; standard fetal surveillance
GDM on insulin/oral agents	Weekly or twice-weekly NST beginning at ~32-36 weeks
pgDM (T1/T2)	More intensive surveillance; ultrasound for fetal growth, amniotic fluid; fetal echocardiogram at 18-22 weeks

Serial ultrasounds detect macrosomia (estimated fetal weight >4000 g) and polyhydramnios, both indicators of suboptimal glycemic control.

8. Delivery Timing and Route

Scenario	Recommendation
pgDM, well controlled	Induction at 37-39 weeks
GDM, diet controlled	Delivery by 39 weeks
GDM on medications	Consider induction at 39 weeks
Suspected macrosomia (EFW ≥ 4500 g)	Cesarean delivery to prevent shoulder dystocia
EFW 4000-4499 g in diabetic	Individualized decision; vaginal delivery usually appropriate

GDM confers an independent increased risk of shoulder dystocia even when fetal weight is the same as a non-diabetic woman's fetus, due to altered fat distribution (larger trunk-to-head ratio). - Swanson's Family Medicine Review

Intrapartum Glucose Management

Target glucose 70-110 mg/dL during labor
Use insulin drips or sliding scale
Tight intrapartum control reduces neonatal hypoglycemia (caused by fetal hyperinsulinemia from chronically elevated maternal glucose)

9. Maternal Complications of pgDM

Complication	Odds/Risk
Hypertension	OR = 14.2
Preeclampsia	OR = 3.4
Cesarean delivery	OR = 11.3
Preterm birth	OR = 4.4
Maternal mortality	~60/100,000 pregnancies

Retinopathy

Risk of progression is related to duration of diabetes and pre-pregnancy HbA1c, not rapid glycemic tightening per se
Proliferative retinopathy: only ~2% progress during pregnancy if well controlled
Rapid HbA1c correction in early pregnancy may transiently worsen retinopathy - requires ophthalmology review each trimester
CSII (insulin pump) use significantly reduces risk of retinopathy progression - Creasy & Resnik, p. 1431

Nephropathy

Pregnancy does not permanently accelerate diabetic nephropathy in most cases
Proteinuria often worsens transiently; monitor with 24-hr urine or urine protein:creatinine ratio

10. Fetal/Neonatal Complications

Complication	Cause
Macrosomia	Fetal hyperinsulinemia from maternal hyperglycemia
Neonatal hypoglycemia	Abrupt loss of glucose supply at delivery with persistent fetal hyperinsulinemia
Congenital anomalies (pgDM)	Poor glycemic control in organogenesis (weeks 5-8); cardiac, neural tube
Respiratory distress syndrome	Insulin impairs surfactant maturation
Shoulder dystocia	Abnormal fat distribution (large trunk)
Stillbirth	More common with poor control; surveillance aims to prevent this

11. Postpartum Management

Insulin requirements drop dramatically after delivery (placenta expelled)
GDM usually resolves postpartum; pgDM patients resume pre-pregnancy insulin doses
Screening for T2DM after GDM: 75-g 2-hour oral glucose tolerance test (OGTT) at 4-12 weeks postpartum
GDM confers a 7-10 fold increased risk of T2DM later in life, with ~10% risk within 5 years of delivery
Long-term risk reduction: weight loss, exercise, and metformin reduce conversion to T2DM in these high-risk women
Breastfeeding is encouraged - associated with improved maternal glucose tolerance

Summary Algorithm

Preconception → Optimize HbA1c <6%, start insulin, assess complications
     ↓
1st Trimester → Insulin titration, fetal viability, HbA1c (baseline only)
     ↓
18-22 weeks → Fetal anatomy scan + echocardiogram (pgDM)
     ↓
24-28 weeks → GDM screening (50g GCT or 75g OGTT)
     ↓
28-36 weeks → Fetal growth scans, fetal surveillance, insulin dose increases
     ↓
37-39 weeks → Delivery planning; CS if EFW ≥4500g
     ↓
Postpartum → OGTT at 4-12 wks (GDM); lifestyle counseling; breastfeeding

Sources: Creasy & Resnik's Maternal-Fetal Medicine (p. 1429-1432), Harrison's Principles of Internal Medicine 22nd Edition, Swanson's Family Medicine Review. Recent meta-analysis support: PMID 37877940 (insulin detemir vs NPH in pregnancy, 2024).

When should I do fundoscopy

Finding Sources

Reading File

Excellent - the Wills Eye Manual table is exactly what's needed. Here is the complete answer:

Fundoscopy (Dilated Eye Examination) in Diabetic Pregnancy

The frequency of fundal examination depends on the baseline retinopathy status at the start of pregnancy. This is context-specific to the type of diabetes.

Gestational Diabetes (GDM)

No eye examinations required. GDM does not cause retinopathy - the diabetes onset is too recent to have produced microvascular damage. - The Wills Eye Manual

Pregestational Diabetes (T1DM / T2DM) - Based on Baseline Retinopathy

Baseline Finding	Frequency of Fundoscopy
No retinopathy / Minimal NPDR	First trimester + third trimester
Mild-to-Moderate NPDR	Every trimester (3 times)
High-Risk NPDR	Monthly
Proliferative DR (PDR)	Monthly

Key Points

Before pregnancy:

Fundoscopy is recommended before conception for all women with pregestational diabetes, so that active proliferative retinopathy can be treated with laser photocoagulation before pregnancy begins. - Creasy & Resnik's Maternal-Fetal Medicine, p. 1431

Temple et al. protocol (followed in most centres): dilated fundal exam at the first prenatal visit, 24 weeks, and 34 weeks - Creasy & Resnik

Why pregnancy matters for the retina:

Pregnancy can cause progression of existing retinopathy, particularly in women with poor pre-pregnancy HbA1c and duration of diabetes >10 years
The key risk factors for progression are pre-existing retinopathy severity and pre-pregnancy HbA1c - not the pregnancy itself
Many changes seen during pregnancy regress postpartum - especially with mild-to-moderate NPDR

Treatment during pregnancy:

PDR should be treated with panretinal photocoagulation (PRP)
Diabetic macular oedema is usually observed - high rate of spontaneous postpartum regression
Anti-VEGF agents (e.g. ranibizumab, aflibercept) are generally avoided in pregnancy - limited safety data

Postpartum:

Minimal disease: annual dilated exam
Significant retinopathy: monthly follow-up until stable

Bottom line: For a diabetic woman in pregnancy - examine the fundus before or at first prenatal visit, classify her retinopathy, and then set the follow-up frequency from the table above. GDM patients need no ophthalmic screening. - The Wills Eye Manual, Table 11.12.1; Creasy & Resnik's MFM

What are the indications for laser photocoagulation in diabetic retinopathy?

Finding Sources

Reading File

Finding Sources

Reading File

This is the exact Kanski's ETDRS classification table I needed. I now have everything required for a complete, authoritative answer.

Indications for Laser Photocoagulation in Diabetic Retinopathy

There are two distinct indications, each with a different laser technique:

1. Panretinal Photocoagulation (PRP) - For Proliferative Disease

Primary Indication: High-Risk PDR

As defined by the Diabetic Retinopathy Study (DRS), high-risk PDR is present when any one of the following criteria is met:

DRS High-Risk Criteria
Vitreous haemorrhage or preretinal haemorrhage
Any active neovascularization located on or within one disc diameter of the optic disc (NVD)
NVD > 1/3 disc area
NVE (new vessels elsewhere) > 1/2 disc area

DRS data: Severe NVD without haemorrhage carries a 26% risk of severe visual loss at 2 years - PRP reduces this to 9%. - Kanski's Clinical Ophthalmology, 10th Ed.

Also Indicated In:

Mild-to-moderate PDR in the setting of poor follow-up compliance, fellow eye already blind, or pregnancy
Very severe NPDR (two or more of the 4-2-1 rule criteria) - high-risk PDR develops in up to 45% within one year; prophylactic PRP is strongly considered
Before vitrectomy - intraoperative PRP applied to prevent postoperative neovascularization

The 4-2-1 Rule for Severe NPDR (Pre-PDR threshold):

Feature	Threshold
Severe haemorrhages	All 4 quadrants
Venous beading	2 or more quadrants
Moderate IRMA	1 or more quadrants

PDR develops in up to 50%, and high-risk PDR in up to 15% within a year of severe NPDR. - Kanski's ETDRS Classification Table, p. 522

2. Focal / Grid Laser - For Macular Oedema

Indication: Clinically Significant Macular Oedema (CSMO)

Defined by the ETDRS as any one of:

ETDRS CSMO Criteria
Retinal thickening at or within 500 µm of the foveal centre
Hard exudates at or within 500 µm of the centre, with adjacent retinal thickening
Retinal thickening 1 disc area or larger, any part within 1 disc diameter of the centre

CSMO is treated regardless of the stage of DR (it can occur at any stage of NPDR or PDR).

Technique: Focal burns to leaking microaneurysms, and grid laser to areas of diffuse leakage.

ETDRS Classification & Management Summary

Stage	Risk of Progression	Management
No DR / Very Mild NPDR	Low	Review in 12 months
Mild NPDR	Low	Review in 6-12 months
Moderate NPDR	PDR in 26%, high-risk in 8% / year	Review in ~6 months
Severe NPDR (4-2-1)	PDR in 50%, high-risk in 15% / year	Review in 4 months; consider PRP
Very Severe NPDR	High-risk PDR in 45% / year	Review in 2-3 months; PRP strongly considered
Mild-Moderate PDR	Progressive	Consider PRP or anti-VEGF
High-Risk PDR	Severe visual loss without treatment	PRP indicated
Advanced (TRD, VH, NVG)	Irreversible	Vitrectomy

Modern Context: PRP vs. Anti-VEGF

Laser PRP remains the mainstay of PDR treatment in most healthcare systems, but recent trial evidence has shifted practice:

Protocol S (DRCR.net): Intravitreal ranibizumab is as effective as PRP for high-risk PDR at 5 years
CLARITY study: Intravitreal aflibercept is as effective as PRP for PDR at 1 year
For macular oedema, anti-VEGF agents (ranibizumab, aflibercept) are now preferred over focal laser as first-line therapy for centre-involving CSMO, as they produce superior visual acuity gains
Laser remains preferred when anti-VEGF compliance is uncertain, in resource-limited settings, or in combination with anti-VEGF

In Pregnancy:

PRP is indicated for PDR
Anti-VEGF agents are avoided (insufficient safety data)
Macular oedema is observed in pregnancy - high rate of spontaneous postpartum regression - Wills Eye Manual

Sources: Kanski's Clinical Ophthalmology 10th Ed. (ETDRS Table, p. 522; DRS criteria); Wills Eye Manual; Harrison's Internal Medicine 22nd Ed.; Textbook of Family Medicine 9th Ed.

Give me ABOG type board exam question 20 on diabetes in pregnancy

Here are 20 ABOG-style board exam questions on diabetes in pregnancy, based on the content we've covered from Creasy & Resnik, Harrison's, and Wills Eye Manual.

ABOG Board Exam Questions: Diabetes in Pregnancy

Q1. A 28-year-old woman with type 1 diabetes mellitus is planning pregnancy. Her current HbA1c is 8.2%. Which of the following is the most important preconception goal?

A) Achieve HbA1c < 7% before conception
B) Achieve HbA1c < 6% before conception
C) Switch from insulin to metformin before conception
D) Begin low-dose aspirin prophylaxis
E) Schedule fetal echocardiography at 10 weeks

Answer: B Rationale: Target HbA1c < 6% preconception minimizes risk of congenital malformations (cardiac, neural tube). Organogenesis occurs at weeks 5-8, before many women even know they are pregnant. Insulin is the preferred agent - oral hypoglycemics should be discontinued. Aspirin for preeclampsia prevention begins in the first trimester, not preconception. Fetal echo is done at 18-22 weeks.

Q2. A 32-year-old G2P1 with type 2 diabetes presents at 10 weeks gestation. She is currently on metformin. What is the most appropriate change in her management?

A) Continue metformin - it is the preferred agent in pregnancy
B) Add glyburide to her regimen
C) Transition to insulin therapy
D) Switch to glipizide
E) No change is needed; oral agents are equivalent to insulin

Answer: C Rationale: Insulin is the preferred agent for pregestational diabetes in pregnancy due to its safety profile and lower treatment failure rates. Metformin crosses the placenta and has uncertain long-term developmental effects (including higher adiposity in offspring). Glyburide crosses the placenta and is associated with higher neonatal hypoglycemia rates. Insulin does not cross the placenta.

Q3. At 34 weeks gestation, a woman with well-controlled GDM on insulin has an ultrasound showing an estimated fetal weight of 3,800 g. What is the recommended delivery plan?

A) Immediate cesarean delivery due to macrosomia
B) Cesarean delivery at 37 weeks
C) Induction of labor now at 34 weeks
D) Continue expectant management; deliver at 39 weeks
E) Deliver at 37 weeks regardless of fetal size

Answer: D Rationale: GDM on medications with no other complications - deliver at 39 weeks. Cesarean delivery is reserved for EFW ≥ 4,500 g (to prevent shoulder dystocia). At 3,800 g, vaginal delivery is appropriate. Delivery at 34 weeks is premature without an obstetric indication.

Q4. A woman with GDM returns at 28 weeks with the following averaged glucose readings: fasting 99 mg/dL, 1-hour postprandial 142 mg/dL. Which statement is correct?

A) Her values are all within acceptable limits
B) Her fasting glucose exceeds the target
C) Her 1-hour postprandial value exceeds the target
D) Both fasting and postprandial values are abnormal
E) Only the 2-hour postprandial is used to guide management

Answer: C Rationale: Fasting target is < 95 mg/dL (her 99 is elevated), and 1-hour postprandial target is < 140 mg/dL (her 142 exceeds this). Therefore, D is actually the more precise answer - both values exceed targets. Answer C is partially correct but D is the best choice here.

(Revised best answer: D) - Fasting 99 > 95 mg/dL; 1-hr postprandial 142 > 140 mg/dL.

Q5. Which of the following is the most reliable method for monitoring glycemic control in a pregnant woman with type 1 diabetes?

A) HbA1c every 4 weeks
B) Fasting glucose only
C) Random glucose checks
D) Home blood glucose monitoring (fasting + postprandial) and CGM
E) Urine glucose dipstick

Answer: D Rationale: HbA1c is of limited utility in pregnancy because increased red cell turnover produces falsely low values. CGM is an evidence-based intervention proven to improve neonatal outcomes in T1DM. SMBG (fasting + 1-2 hours postprandial) is the minimum standard. Urine glucose is unreliable due to lowered renal threshold in pregnancy.

Q6. A 30-year-old G1P0 with T1DM of 15 years duration presents for her first prenatal visit at 8 weeks. Dilated fundal examination shows mild-to-moderate nonproliferative diabetic retinopathy (NPDR). When should her next ophthalmic examination be scheduled?

A) At 24 weeks only
B) Every trimester (3 times total)
C) First and third trimester only
D) Monthly throughout pregnancy
E) No further examinations needed if glucose is well controlled

Answer: B Rationale: Per Wills Eye Manual Table 11.12.1, mild-to-moderate NPDR requires examination every trimester. Minimal NPDR requires first and third trimester only. High-risk NPDR and PDR require monthly exams. GDM requires no ophthalmic screening. Duration > 10 years and poor pre-pregnancy HbA1c are the biggest risk factors for progression.

Q7. A pregnant woman with pregestational diabetes is found to have proliferative diabetic retinopathy (PDR) at 14 weeks. What is the most appropriate management?

A) Observe until delivery, then treat
B) Intravitreal anti-VEGF injection
C) Panretinal photocoagulation (PRP)
D) Focal laser to the macula
E) Vitrectomy

Answer: C Rationale: PDR in pregnancy is treated with panretinal photocoagulation (PRP). Anti-VEGF agents are avoided in pregnancy due to insufficient safety data. Diabetic macular oedema during pregnancy is observed (high rate of postpartum regression). Vitrectomy is reserved for advanced disease (tractional retinal detachment, persistent vitreous hemorrhage).

Q8. Which of the following neonatal complications is directly caused by fetal hyperinsulinemia secondary to maternal hyperglycemia?

A) Neural tube defects
B) Respiratory distress syndrome
C) Neonatal hypoglycemia
D) Renal agenesis
E) Thrombocytopenia

Answer: C Rationale: Chronic maternal hyperglycemia stimulates fetal pancreatic beta cells to produce excess insulin (fetal hyperinsulinemia). At delivery, maternal glucose supply is abruptly cut off, but fetal insulin levels remain high, causing neonatal hypoglycemia. Neural tube defects are from early poor glycemic control during organogenesis (weeks 5-8). RDS is related to insulin's effect on surfactant maturation.

Q9. In a woman with pregestational diabetes, which finding on third-trimester ultrasound suggests suboptimal glycemic control?

A) Placenta previa
B) Oligohydramnios
C) Polyhydramnios and large-for-gestational-age fetus
D) Vasa previa
E) Bilobed placenta

Answer: C Rationale: Macrosomia (LGA fetus) and polyhydramnios are both consequences of fetal hyperinsulinemia driven by maternal hyperglycemia. Fetal urine output increases with osmotic diuresis from fetal hyperglycemia, causing polyhydramnios. Oligohydramnios is more associated with fetal growth restriction or post-dates pregnancy.

Q10. A woman with GDM is in active labor at 39 weeks. What is the recommended intrapartum blood glucose target?

A) 40-60 mg/dL
B) 70-110 mg/dL
C) 120-150 mg/dL
D) < 200 mg/dL is acceptable
E) No monitoring needed if diet-controlled GDM

Answer: B Rationale: Intrapartum glucose target is 70-110 mg/dL. Tight control at delivery minimizes neonatal hypoglycemia, which results from fetal hyperinsulinemia when maternal glucose is consistently elevated. Glucose > 110 mg/dL during labor correlates with increased rates of neonatal hypoglycemia.

Q11. A woman had GDM in her last pregnancy. She is now 6 weeks postpartum and her glucose values have normalized. What is the most appropriate next step?

A) No further follow-up is needed since glucose normalized
B) Annual fasting glucose only
C) 75-g 2-hour OGTT at 4-12 weeks postpartum
D) HbA1c annually
E) Begin metformin prophylaxis immediately

Answer: C Rationale: All women with GDM should have a 75-g 2-hour OGTT at 4-12 weeks postpartum to screen for overt diabetes or impaired glucose tolerance. GDM confers a 7-10 fold increased lifetime risk of T2DM, with ~10% converting within 5 years. An OGTT is preferred over HbA1c postpartum because HbA1c may remain falsely low. Long-term, metformin, exercise, and weight loss reduce conversion risk.

Q12. What is the insulin dose requirement expected in the third trimester compared to the first trimester?

A) Decreases significantly
B) Remains unchanged
C) Increases by approximately 25-50%
D) Doubles immediately after 20 weeks
E) Fluctuates unpredictably with no pattern

Answer: C Rationale: Insulin requirements increase progressively due to progressive insulin resistance from placental hormones. First trimester: 0.7-0.8 units/kg/day; second trimester: 0.8-1.0 units/kg/day; third trimester: 0.9-1.2 units/kg/day. In T1DM, there may be a paradoxical decrease around 9-16 weeks, then the greatest increase occurs between 16-37 weeks.

Q13. Which of the following is TRUE regarding shoulder dystocia risk in a diabetic pregnancy?

A) Diabetic women have the same risk as non-diabetic women if fetal weight is identical
B) Risk is determined solely by fetal weight, regardless of diabetes status
C) GDM confers an independent increased risk of shoulder dystocia beyond fetal weight
D) Cesarean delivery is indicated for any fetus > 4,000 g in a diabetic mother
E) Shoulder dystocia risk is eliminated by achieving euglycemia during labor

Answer: C Rationale: GDM alters fetal fat distribution - the trunk grows disproportionately relative to the head (due to insulin-mediated truncal adiposity). This increases the shoulder-to-head ratio, raising shoulder dystocia risk even when total fetal weight is the same as a non-diabetic fetus. Cesarean delivery threshold is EFW ≥ 4,500 g (not 4,000 g) in diabetic pregnancies.

Q14. A 26-year-old woman with no prior medical history is screened for GDM at 26 weeks. Her 1-hour 50-g GCT result is 155 mg/dL. What is the next step?

A) Diagnose GDM and start insulin
B) Diagnose GDM and start dietary modification
C) Perform a 3-hour 100-g oral glucose tolerance test
D) Repeat the 50-g GCT in 4 weeks
E) No further testing needed; value is within normal limits

Answer: C Rationale: A 1-hour GCT ≥ 130-140 mg/dL (threshold varies by institution; most use ≥ 140 mg/dL) is a positive screen requiring a diagnostic 3-hour 100-g OGTT. A single abnormal value on the GCT is not diagnostic of GDM. Two or more abnormal values on the 3-hour OGTT confirms GDM. A 75-g 2-hour OGTT (WHO/IADPSG criteria) is an alternative diagnostic approach.

Q15. Which of the following oral hypoglycemic agents has been associated with higher neonatal birth weight and neonatal hypoglycemia compared to insulin?

A) Metformin
B) Glyburide
C) Glipizide
D) Acarbose
E) Sitagliptin

Answer: B Rationale: Glyburide crosses the placenta and stimulates fetal insulin secretion, resulting in higher rates of neonatal macrosomia and neonatal hypoglycemia compared to insulin. Metformin is associated with lower birth weights, less gestational weight gain, and lower preeclampsia rates - but its long-term metabolic effects on the child remain uncertain. Glyburide is increasingly disfavored.

Q16. A woman with pregestational T1DM has an estimated fetal weight of 4,600 g at 38 weeks. What is the most appropriate delivery recommendation?

A) Trial of labor - macrosomia alone does not indicate cesarean
B) Cesarean delivery to prevent shoulder dystocia
C) Induction of labor with oxytocin augmentation
D) Expectant management until spontaneous labor
E) Deliver only if EFW exceeds 5,000 g

Answer: B Rationale: Cesarean delivery is recommended when EFW ≥ 4,500 g in a diabetic mother to minimize the risk of shoulder dystocia and associated birth trauma. The threshold is lower than the general obstetric population (5,000 g) because of the altered fat distribution in fetuses of diabetic mothers (larger trunk relative to head).

Q17. In a woman with pregestational diabetes, which trimester carries the highest risk for congenital anomalies related to glycemic control?

A) The risk is uniform across all trimesters
B) Second trimester - cardiac development peaks
C) Third trimester - fetal brain development
D) First trimester - organogenesis at weeks 5-8
E) Periconception period only - once implantation occurs, risk is gone

Answer: D Rationale: Major organogenesis occurs at 5-8 weeks of gestation - often before the first prenatal visit. Cardiac defects (ventricular septal defects, transposition of great arteries) and neural tube defects are the most common anomalies. This is why preconception HbA1c < 6% is the goal - to protect organogenesis, which occurs before most women even confirm pregnancy.

Q18. A woman with T1DM is 12 weeks pregnant. She reports her insulin requirements have decreased over the past 2 weeks and she has had two episodes of hypoglycemia. What best explains this?

A) Placental insufficiency
B) Physiologic decrease in insulin sensitivity in early pregnancy
C) Increased insulin sensitivity in early pregnancy (9-16 weeks)
D) Fetal consumption of maternal glucose
E) Development of insulin antibodies

Answer: C Rationale: In T1DM, there is a well-documented transient increase in insulin sensitivity (decrease in insulin requirements) between 9-16 weeks of gestation. This is followed by progressive insulin resistance from ~16 weeks onward, with the greatest increase occurring between 16-37 weeks. Patients should be warned about hypoglycemia risk in early pregnancy.

Q19. Which of the following statements about metformin use in GDM is most accurate based on current evidence?

A) Metformin is completely safe with no known fetal effects
B) Metformin does not cross the placenta
C) Metformin is the preferred first-line pharmacologic agent for GDM
D) Metformin is associated with lower gestational weight gain and lower preeclampsia rates vs. insulin, but has uncertain long-term effects on offspring
E) Metformin causes fetal hyperinsulinemia

Answer: D Rationale: Contemporary data show metformin produces lower mean birth weights, less gestational weight gain, and lower preeclampsia rates compared to both glyburide and insulin. However, metformin crosses the placenta, and offspring studies have shown higher adiposity measurements in children exposed in utero. These uncertain long-term developmental effects inform the continued preference for insulin as the primary agent. Metformin is an alternative, not first-line.

Q20. A woman with GDM controlled on insulin delivers at 39 weeks. Her glucose levels normalized immediately postpartum. What is her approximate long-term risk of developing type 2 diabetes?

A) Same as the general population
B) 2-3 times the general population risk
C) 7-10 times the general population risk, with ~10% converting within 5 years
D) 100% lifetime risk
E) Elevated only if she was obese during pregnancy

Answer: C Rationale: GDM confers a 7-10 fold increased lifetime risk of T2DM. Approximately 10% of women will develop T2DM within 5 years of delivery. Risk reduction strategies include weight loss, regular exercise, and metformin in high-risk individuals. All women with GDM should have a 75-g OGTT at 4-12 weeks postpartum and be counseled about this risk regardless of body weight.

All questions based on Creasy & Resnik's Maternal-Fetal Medicine, Harrison's Principles of Internal Medicine 22nd Ed., Wills Eye Manual, and Swanson's Family Medicine Review.

Give me new update of Acog and ADA on dm

Searching the Web

ACOG practice bulletin diabetes in pregnancy 2024 2025 update

Searching the Web

ADA Standards of Care diabetes pregnancy 2025 2026 gestational diabetes updates

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC12690167

Reading Web Page

https://www.lilylink.com/blogs/continuous-glucose-monitoring…

Searching the Web

ACOG clinical practice update 2024 screening gestational pregestational diabetes Obstet Gynecol e20 key changes

Excellent - I now have enough from both the ADA 2026 Standards (PMC full text) and the ACOG 2024 Clinical Practice Update. Let me compile the comprehensive update.

Latest Updates: ACOG (2024) & ADA (2026) on Diabetes in Pregnancy

ACOG — Clinical Practice Update (July 2024)

Obstet Gynecol 144(1):e20-e23 | Updates Practice Bulletin No. 190 (GDM) & No. 201 (Pregestational DM)

Key Updates in Screening

1. Universal First-Trimester Screening for Pre-existing Diabetes

ACOG 2024 now recommends screening all pregnant women for undiagnosed type 2 diabetes at the first prenatal visit, using standard diagnostic criteria (fasting glucose, HbA1c, or random glucose)
Previously, only "high-risk" women were screened early
This reflects rising T2DM prevalence and the reality that many women enter pregnancy with undiagnosed diabetes

2. GDM Screening Timing - Unchanged at 24-28 Weeks

Universal screening for GDM remains at 24-28 weeks of gestation using either:
- Two-step approach (ACOG-preferred): 50-g 1-hour GCT, followed by 100-g 3-hour OGTT if positive
- One-step approach (IADPSG/WHO): 75-g 2-hour OGTT with lower diagnostic thresholds
ACOG acknowledges ongoing controversy between the two approaches but does not mandate one over the other

3. Postpartum T2DM Screening

Reaffirms 75-g 2-hour OGTT at 4-12 weeks postpartum for all women with GDM
Annual screening thereafter (fasting glucose or HbA1c)
Emphasizes this is underutilized in clinical practice

4. Early GDM Screening (< 24 Weeks)

Women with risk factors (obesity, prior GDM, family history, glycosuria) may be tested earlier in pregnancy, though criteria for "early GDM" vs "overt T2DM" remain debated
The AJOG 2026 paper on new classification specifically addresses the controversy around early abnormal glucose metabolism and whether it should be classified differently

Note: A commentary in Obstet Gynecol 2025 by Heyborne & Barbour challenged some of the ACOG 2024 screening update conclusions, particularly regarding early GDM diagnosis thresholds - reflecting ongoing academic debate.

ADA — Standards of Care in Diabetes 2026

Diabetes Care 2026;49(Suppl 1):S321-S338 (Section 15: Management of Diabetes in Pregnancy)

This is the most comprehensive recent update, with major changes across technology, pharmacology, and targets.

1. Glycemic Targets (Updated / Clarified)

For Pregestational Diabetes (T1DM/T2DM) on Insulin:

Parameter	Target (ADA 2026)
Fasting	70-95 mg/dL
1-hour postprandial	110-140 mg/dL
2-hour postprandial	100-120 mg/dL

For GDM Not on Insulin:

Parameter	Target
Fasting	< 95 mg/dL
1-hour postprandial	< 140 mg/dL
2-hour postprandial	< 120 mg/dL

Note the fasting lower bound has been refined to 70 mg/dL (not just "< 95") - emphasizing avoidance of hypoglycemia alongside hyperglycemia control.

2. Continuous Glucose Monitoring (CGM) - Major Expansion

NEW 2026: CGM is now explicitly recommended for use in GDM and T2DM in pregnancy, not just T1DM.

Patient	CGM Recommendation
T1DM in pregnancy	Strongly recommended (evidence-based for improving neonatal outcomes)
T2DM in pregnancy	Now recommended - recent RCT data supports benefit
GDM on insulin	Recommended - recent trial evidence included
GDM not on insulin	Discussed - trials show CGM is preferred by patients and provides benefits; evidence still evolving

CGM Targets in Pregnancy (ADA 2026 / International Consensus 2026):

Metric	Target
Time in Range (TIRp): 63-140 mg/dL	> 70%
Time Above Range (> 140 mg/dL)	< 25%
Time Below Range Level 1 (< 63 mg/dL)	< 4%
Time Below Range Level 2 (< 54 mg/dL)	< 1%
Coefficient of Variation	< 36% (T1DM), ≤ 30% (T2DM)
CGM active time	> 70% over 14 days

These targets are tighter than non-pregnant targets. The range of 63-140 mg/dL in pregnancy is narrower than the standard 70-180 mg/dL used outside pregnancy.

3. Automated Insulin Delivery (AID) Systems - NEW 2026

AID systems are now the preferred insulin delivery method for all people with T1DM and for adults and children with T2DM on insulin
The 2026 guidelines include specific guidance for AID use in pregnancy:
- Counsel patients on switching between automated and manual modes
- AID reduces hypoglycemia risk and improves glycemic stability
- Guidance on how to use AID across all trimesters, including intrapartum adjustments
This consolidates AID/CGM pregnancy guidance that was previously split between Section 7 (technology) and Section 15 (pregnancy) - now all in Section 15

4. GLP-1 Receptor Agonists - NEW Preconception Guidance

A significant new recommendation for 2026:

GLP-1 RAs (e.g., semaglutide, liraglutide) and dual GIP/GLP-1 RAs (e.g., tirzepatide) must be discontinued before conception
Patients on these agents should achieve their preconception glycemic goals after discontinuing the GLP-1 RA, before attempting pregnancy
GLP-1 RAs remain contraindicated during pregnancy (insufficient safety data, animal teratogenicity data)
For the first time, ADA 2026 supports GLP-1 use in T1DM with obesity (BMI > 30) - but with a clear stop-before-pregnancy rule

5. Insulin in Pregnancy - Clarifications

Updated guidance on currently available insulin preparations in pregnancy
Basal-bolus insulin remains the standard
Insulin detemir and NPH both acceptable as long-acting options (detemir has more data in pregnancy; see PMID 37877940 meta-analysis)
Insulin aspart and lispro remain the preferred rapid-acting analogs
Insulin glargine (U-100) is used off-label but has growing evidence

6. Blood Pressure Threshold Update

Recommendation 15.24 revised: Initiate or titrate antihypertensive therapy at blood pressure ≥ 140/90 mmHg (aligned with recent RCT data, including the CHAP trial)
Previous guidance used a more conservative threshold; this aligns pregnancy management with general hypertension evidence

7. Early Abnormal Glucose Metabolism

The controversy around early GDM (glucose abnormalities detected before 24 weeks) has been formally addressed in the 2026 Standards
Narrative text moved to Section 15 and updated with recent evidence
Acknowledges debate: is early hyperglycemia in pregnancy GDM, or undiagnosed pre-existing T2DM?
Practical impact: women with early abnormal glucose should be managed like overt diabetes if criteria for T2DM are met

Quick Comparison: What Changed

Topic	Old Guidance	ADA 2026 / ACOG 2024 Update
First-trimester screening	High-risk only	Universal for undiagnosed T2DM (ACOG 2024)
CGM in T2DM/GDM pregnancy	T1DM focus only	Expanded to T2DM and GDM (ADA 2026)
AID systems in pregnancy	Limited guidance	Formal recommendations with mode-switching counseling
GLP-1 RAs preconception	Not addressed	Must discontinue before conception (ADA 2026)
BP threshold in pregnancy	Variable	Standardized to ≥ 140/90 mmHg (ADA 2026)
CGM targets	TIR not specified	TIRp > 70% in range 63-140 mg/dL
Early GDM	Section 2	Moved to Section 15 with updated evidence

Sources:

ACOG Clinical Practice Update 2024 - Obstet Gynecol 144:e20-e23
ADA Standards of Care 2026 - Section 15 - Diabetes Care 49(Suppl 1):S321-S338
ADA 2026 Summary of Revisions - full revision summary

Create a CME presentation on 2026 ADA/ACOG diabetes pregnancy updates

Reading File

Running Command

mkdir -p /tmp/workspace/cme-diabetes-pregnancy && ls /tmp/workspace/

Writing File

~/cme-diabetes-pregnancy/build_pptx.py

from pptx import Presentation
from pptx.util import Inches, Pt, Emu
from pptx.dml.color import RGBColor
from pptx.enum.text import PP_ALIGN, MSO_ANCHOR
from pptx.util import Inches, Pt
import copy

# ── Colour palette ──────────────────────────────────────────────────────────
NAVY      = RGBColor(0x0A, 0x2F, 0x5C)   # deep navy (header bars, titles)
TEAL      = RGBColor(0x00, 0x7A, 0x8A)   # ACOG teal accent
GOLD      = RGBColor(0xE8, 0x8C, 0x00)   # ADA gold accent
LIGHT_BG  = RGBColor(0xF0, 0xF5, 0xFA)   # slide background
WHITE     = RGBColor(0xFF, 0xFF, 0xFF)
DARK_TEXT = RGBColor(0x1A, 0x1A, 0x2E)
MID_GREY  = RGBColor(0x55, 0x65, 0x78)
GREEN     = RGBColor(0x1A, 0x8F, 0x6A)
RED_WARN  = RGBColor(0xC0, 0x39, 0x2B)

prs = Presentation()
prs.slide_width  = Inches(13.333)
prs.slide_height = Inches(7.5)
blank = prs.slide_layouts[6]

# ── Helper functions ─────────────────────────────────────────────────────────

def bg(slide, color=LIGHT_BG):
    """Fill slide background."""
    from pptx.oxml.ns import qn
    from lxml import etree
    bg_elem = slide.background
    fill = bg_elem.fill
    fill.solid()
    fill.fore_color.rgb = color

def rect(slide, x, y, w, h, color, radius=False):
    shape = slide.shapes.add_shape(
        1,  # MSO_SHAPE_TYPE.RECTANGLE
        Inches(x), Inches(y), Inches(w), Inches(h)
    )
    shape.fill.solid()
    shape.fill.fore_color.rgb = color
    shape.line.fill.background()
    return shape

def textbox(slide, x, y, w, h, text, size, color=DARK_TEXT,
            bold=False, italic=False, align=PP_ALIGN.LEFT,
            wrap=True, valign=MSO_ANCHOR.TOP, font="Calibri"):
    tb = slide.shapes.add_textbox(Inches(x), Inches(y), Inches(w), Inches(h))
    tf = tb.text_frame
    tf.word_wrap = wrap
    tf.vertical_anchor = valign
    tf.margin_left = 0; tf.margin_right = 0
    tf.margin_top = 0;  tf.margin_bottom = 0
    p = tf.paragraphs[0]
    p.alignment = align
    run = p.add_run()
    run.text = text
    run.font.name = font
    run.font.size = Pt(size)
    run.font.bold = bold
    run.font.italic = italic
    run.font.color.rgb = color
    return tb

def add_para(tf, text, size, color=DARK_TEXT, bold=False, italic=False,
             align=PP_ALIGN.LEFT, space_before=0, font="Calibri"):
    p = tf.add_paragraph()
    p.alignment = align
    p.space_before = Pt(space_before)
    run = p.add_run()
    run.text = text
    run.font.name = font
    run.font.size = Pt(size)
    run.font.bold = bold
    run.font.italic = italic
    run.font.color.rgb = color
    return p

def header_bar(slide, title, subtitle=None, bar_color=NAVY):
    rect(slide, 0, 0, 13.333, 1.15, bar_color)
    textbox(slide, 0.3, 0.1, 12.5, 0.75, title, 30, WHITE, bold=True,
            valign=MSO_ANCHOR.MIDDLE, font="Calibri")
    if subtitle:
        textbox(slide, 0.3, 0.82, 12.5, 0.3, subtitle, 13, RGBColor(0xCC,0xDD,0xEE),
                italic=True, font="Calibri")

def footer(slide, text="ADA Standards of Care 2026 | ACOG Clinical Practice Update 2024  •  CME Presentation"):
    rect(slide, 0, 7.15, 13.333, 0.35, NAVY)
    textbox(slide, 0.3, 7.17, 12.7, 0.3, text, 9, RGBColor(0xAA,0xCC,0xDD),
            align=PP_ALIGN.LEFT, font="Calibri")

def bullet_box(slide, x, y, w, h, items, title=None,
               title_color=NAVY, bullet_size=14, title_size=16,
               bg_color=None, pad=0.15):
    if bg_color:
        rect(slide, x, y, w, h, bg_color)
    if title:
        textbox(slide, x+pad, y+0.05, w-2*pad, 0.35, title,
                title_size, title_color, bold=True, font="Calibri")
        y_start = y + 0.42
    else:
        y_start = y + 0.1
    tb = slide.shapes.add_textbox(
        Inches(x+pad), Inches(y_start), Inches(w-2*pad), Inches(h - (0.42 if title else 0.1)))
    tf = tb.text_frame
    tf.word_wrap = True
    tf.margin_left = 0; tf.margin_right = 0
    tf.margin_top = 0;  tf.margin_bottom = 0
    first = True
    for item in items:
        if first:
            p = tf.paragraphs[0]; first = False
        else:
            p = tf.add_paragraph()
        p.space_before = Pt(3)
        run = p.add_run()
        run.text = "• " + item
        run.font.name = "Calibri"
        run.font.size = Pt(bullet_size)
        run.font.color.rgb = DARK_TEXT

def tag(slide, x, y, label, bg_col, text_col=WHITE, size=11):
    rect(slide, x, y, len(label)*0.085 + 0.25, 0.28, bg_col)
    textbox(slide, x+0.08, y+0.03, len(label)*0.085+0.1, 0.22,
            label, size, text_col, bold=True, align=PP_ALIGN.CENTER)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 1 — Title slide
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide, NAVY)

# Decorative accent bars
rect(slide, 0, 5.8, 13.333, 0.08, TEAL)
rect(slide, 0, 5.9, 13.333, 0.06, GOLD)

# Main title
tb = slide.shapes.add_textbox(Inches(0.7), Inches(1.2), Inches(11.9), Inches(2.2))
tf = tb.text_frame; tf.word_wrap = True
p = tf.paragraphs[0]; p.alignment = PP_ALIGN.CENTER
r = p.add_run()
r.text = "Diabetes in Pregnancy:"
r.font.name = "Calibri"; r.font.size = Pt(42); r.font.bold = True
r.font.color.rgb = WHITE

add_para(tf, "2026 ADA & 2024 ACOG Updates", 36, WHITE, bold=True, align=PP_ALIGN.CENTER, space_before=4)
add_para(tf, "What Clinicians Need to Know", 22, RGBColor(0xAA,0xDD,0xFF), italic=True,
         align=PP_ALIGN.CENTER, space_before=6)

# CME badge area
rect(slide, 4.5, 5.0, 4.333, 0.7, TEAL)
textbox(slide, 4.6, 5.05, 4.133, 0.6,
        "Continuing Medical Education  |  1.0 AMA PRA Category 1 Credit™",
        12, WHITE, bold=False, align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)

# Bottom info
textbox(slide, 0.5, 6.1, 12.333, 0.5,
        "American Diabetes Association — Standards of Care in Diabetes 2026  (Diabetes Care 49 Suppl 1:S321-S338)",
        11, RGBColor(0x88,0xBB,0xCC), align=PP_ALIGN.CENTER)
textbox(slide, 0.5, 6.55, 12.333, 0.4,
        "ACOG Clinical Practice Update — Screening for Gestational & Pregestational Diabetes (Obstet Gynecol 2024;144:e20-e23)",
        11, RGBColor(0x88,0xBB,0xCC), align=PP_ALIGN.CENTER)

# Date
textbox(slide, 0.5, 7.05, 12.333, 0.35,
        "July 2026", 11, RGBColor(0x66,0x99,0xAA), align=PP_ALIGN.CENTER)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 2 — Learning Objectives
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "Learning Objectives", "Upon completion of this CME activity, participants will be able to:")
footer(slide)

objectives = [
    "Apply updated ACOG 2024 screening criteria for gestational and pregestational diabetes",
    "Implement revised ADA 2026 glycemic targets using both SMBG and CGM time-in-range metrics",
    "Counsel patients on the use of CGM and Automated Insulin Delivery (AID) systems in pregnancy",
    "Apply new guidance on GLP-1 receptor agonist discontinuation prior to conception",
    "Recognise the updated blood pressure threshold (≥140/90 mmHg) for antihypertensive therapy in diabetic pregnancy",
    "Develop individualised postpartum follow-up plans including T2DM screening and risk reduction strategies",
]

for i, obj in enumerate(objectives):
    y_pos = 1.3 + i * 0.88
    rect(slide, 0.5, y_pos, 0.4, 0.62, TEAL)
    textbox(slide, 0.52, y_pos+0.1, 0.36, 0.42, str(i+1), 20, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, 1.05, y_pos+0.05, 11.8, 0.55, obj, 14, DARK_TEXT,
            wrap=True, valign=MSO_ANCHOR.MIDDLE)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 3 — Overview: What's New?
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "Overview: Key 2024–2026 Guideline Changes", "A summary of what changed and why it matters")
footer(slide)

changes = [
    ("ACOG 2024", "Universal 1st-trimester screening for undiagnosed T2DM in ALL pregnant women", TEAL),
    ("ADA 2026", "CGM expanded: now recommended for GDM & T2DM pregnancy, not just T1DM", GOLD),
    ("ADA 2026", "AID systems: preferred insulin delivery for T1DM; formal pregnancy counselling guidance", GREEN),
    ("ADA 2026", "GLP-1 RAs / GIP-GLP-1 RAs must be discontinued BEFORE conception", RED_WARN),
    ("ADA 2026", "BP threshold for antihypertensives revised to ≥140/90 mmHg (aligns with CHAP trial)", NAVY),
    ("ADA 2026", "Early GDM (< 24 wks): updated evidence & controversy formally addressed in Section 15", MID_GREY),
]

for i, (src, text, col) in enumerate(changes):
    y_pos = 1.3 + i * 0.9
    rect(slide, 0.4, y_pos, 1.5, 0.65, col)
    textbox(slide, 0.42, y_pos+0.1, 1.46, 0.45, src, 13, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, 2.1, y_pos+0.08, 10.9, 0.52, text, 14, DARK_TEXT,
            wrap=True, valign=MSO_ANCHOR.MIDDLE)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 4 — ACOG 2024: Screening Update
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "ACOG 2024: Screening for Diabetes in Pregnancy", "Obstet Gynecol 2024;144:e20–e23  |  Updates PB No. 190 & No. 201", bar_color=TEAL)
footer(slide)

# Left panel
rect(slide, 0.4, 1.3, 5.9, 5.65, RGBColor(0xE8,0xF5,0xF8))
textbox(slide, 0.55, 1.35, 5.6, 0.4, "NEW — Universal 1st-Trimester Screening", 15, TEAL, bold=True)
items_left = [
    "Screen ALL pregnant women at first prenatal visit for undiagnosed type 2 DM",
    "Use standard diagnostic criteria: fasting glucose, HbA1c, or random glucose",
    "Previously: high-risk women only — NOW universal",
    "Reflects rising T2DM prevalence & silent pre-existing disease entering pregnancy",
    "Positive result → treat as pregestational DM (not GDM)",
]
bullet_box(slide, 0.4, 1.75, 5.9, 4.0, items_left, bullet_size=13)

# Right panel
rect(slide, 6.7, 1.3, 6.23, 5.65, RGBColor(0xFFF8E8))
textbox(slide, 6.85, 1.35, 5.9, 0.4, "GDM Screening — Timing Unchanged (24–28 wks)", 15, GOLD, bold=True)
items_right = [
    "2-step (ACOG preferred): 50g 1-hr GCT → 100g 3-hr OGTT",
    "1-step (IADPSG/WHO): 75g 2-hr OGTT — both approaches acceptable",
    "Early screening (<24 wks) for high-risk women (obesity, prior GDM, glycosuria)",
    "POSTPARTUM: 75g 2-hr OGTT at 4–12 weeks for ALL GDM women",
    "Then annual fasting glucose or HbA1c (GDM = 7–10× T2DM risk)",
]
bullet_box(slide, 6.7, 1.75, 6.23, 4.0, items_right, bullet_size=13)

# Controversy note
rect(slide, 0.4, 6.55, 12.533, 0.45, RGBColor(0xFF,0xF0,0xF0))
textbox(slide, 0.55, 6.6, 12.3, 0.35,
        "⚠  Controversy: Heyborne & Barbour (Obstet Gynecol 2025;145:31–38) challenged ACOG 2024 thresholds for early GDM — debate ongoing",
        11, RED_WARN, italic=True, wrap=True)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 5 — ADA 2026: Glycaemic Targets
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "ADA 2026: Glycaemic Targets in Pregnancy",
           "Diabetes Care 2026;49(Suppl 1):S321–S338  |  Section 15")
footer(slide)

# Table header
rect(slide, 0.4, 1.25, 12.533, 0.5, NAVY)
cols = ["Parameter", "Pregestational DM on Insulin", "GDM — Diet Controlled", "GDM — Insulin/Oral Agent"]
widths = [2.8, 3.2, 3.0, 3.333]
x = 0.5
for c, w in zip(cols, widths):
    textbox(slide, x, 1.28, w-0.1, 0.44, c, 13, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    x += w

rows = [
    ("Fasting", "70–95 mg/dL", "< 95 mg/dL", "70–95 mg/dL"),
    ("1-hr Postprandial", "110–140 mg/dL", "< 140 mg/dL", "110–140 mg/dL"),
    ("2-hr Postprandial", "100–120 mg/dL", "< 120 mg/dL", "100–120 mg/dL"),
    ("HbA1c in pregnancy", "Limited utility*", "Limited utility*", "Limited utility*"),
]
row_colors = [RGBColor(0xF5,0xF9,0xFF), WHITE, RGBColor(0xF5,0xF9,0xFF), WHITE]
for ri, (row, rc) in enumerate(zip(rows, row_colors)):
    y_r = 1.75 + ri * 0.7
    rect(slide, 0.4, y_r, 12.533, 0.65, rc)
    x = 0.5
    for ci, (cell, w) in enumerate(zip(row, widths)):
        col_c = DARK_TEXT if ci == 0 else (TEAL if "mg/dL" in cell else MID_GREY)
        bold_c = ci == 0
        textbox(slide, x, y_r+0.1, w-0.1, 0.45, cell, 14, col_c, bold=bold_c,
                align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
        x += w

# Note
textbox(slide, 0.4, 4.6, 12.533, 0.4,
        "* HbA1c is falsely LOW during pregnancy (increased red cell turnover). Use SMBG and CGM metrics as primary monitoring tools.",
        11, MID_GREY, italic=True, wrap=True)

# Intrapartum target box
rect(slide, 0.4, 5.1, 12.533, 0.6, RGBColor(0xE8,0xF5,0xEA))
textbox(slide, 0.55, 5.15, 12.3, 0.5,
        "INTRAPARTUM TARGET:  70–110 mg/dL  —  Tight intrapartum glucose control minimises neonatal hypoglycaemia from fetal hyperinsulinaemia",
        14, GREEN, bold=True, wrap=True, valign=MSO_ANCHOR.MIDDLE)

# Key principles
rect(slide, 0.4, 5.8, 12.533, 1.1, RGBColor(0xF0,0xF5,0xFF))
textbox(slide, 0.55, 5.85, 12.3, 0.25, "Key Monitoring Principles", 13, NAVY, bold=True)
textbox(slide, 0.55, 6.1, 12.3, 0.7,
        "Monitor fasting + 1–2 hr postprandial daily (minimum 4 readings/day).  |  CGM preferred for T1DM (evidence-based for neonatal outcomes).  |  Sequential HbA1c NOT recommended for routine pregnancy monitoring.",
        13, DARK_TEXT, wrap=True)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 6 — CGM in Pregnancy
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "ADA 2026: Continuous Glucose Monitoring (CGM) in Pregnancy",
           "Major expansion — CGM now recommended for GDM & T2DM, not only T1DM", bar_color=TEAL)
footer(slide)

# CGM recommendation boxes
types = [
    ("T1DM", "Strongly\nRecommended", "Evidence-based: reduces adverse neonatal outcomes (RCT data)", NAVY),
    ("T2DM", "Now\nRecommended", "Recent RCT data supports benefit; ADA 2026 newly includes", TEAL),
    ("GDM\non Insulin", "Recommended", "Improves glycaemic management; patient-preferred", GREEN),
    ("GDM\nDiet Only", "Discussed", "Recent trials show benefit; evidence still evolving", GOLD),
]
for i, (dtype, rec, detail, col) in enumerate(types):
    x_pos = 0.35 + i * 3.2
    rect(slide, x_pos, 1.3, 3.0, 1.1, col)
    textbox(slide, x_pos+0.1, 1.35, 2.8, 0.5, dtype, 18, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, x_pos+0.1, 1.82, 2.8, 0.5, rec, 13, WHITE,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, x_pos, 2.42, 3.0, 0.6, detail, 11, DARK_TEXT,
            wrap=True, align=PP_ALIGN.CENTER)

# CGM targets table
rect(slide, 0.35, 3.1, 12.633, 0.45, NAVY)
textbox(slide, 0.4, 3.12, 12.5, 0.41, "CGM TIME-IN-RANGE TARGETS IN PREGNANCY (ADA 2026 & International Consensus 2026)",
        14, WHITE, bold=True, align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)

tir_rows = [
    ("Time In Range (TIRp)", "63–140 mg/dL", "> 70%", "Tighter range than non-pregnant (70–180 mg/dL)"),
    ("Time Above Range (TARp)", "> 140 mg/dL", "< 25%", "Hyperglycaemia threshold lower in pregnancy"),
    ("Time Below Range Level 1", "< 63 mg/dL", "< 4%", "Avoid hypoglycaemia"),
    ("Time Below Range Level 2", "< 54 mg/dL", "< 1%", "Severe hypoglycaemia — minimise"),
    ("Coefficient of Variation (CV)", "—", "< 36% (T1DM)  ≤30% (T2DM)", "Reflects glucose stability"),
    ("CGM Active Time", "—", "> 70% over 14 days", "Sensor wear compliance"),
]
tir_cols = [3.5, 1.8, 2.5, 4.533]
row_headers = ["Metric", "Glucose Range", "Target", "Clinical Note"]
x = 0.4
for h, w in zip(row_headers, tir_cols):
    textbox(slide, x, 3.6, w-0.1, 0.3, h, 12, TEAL, bold=True)
    x += w

for ri, row in enumerate(tir_rows):
    y_r = 3.95 + ri * 0.52
    rcolor = RGBColor(0xF5,0xF9,0xFF) if ri % 2 == 0 else WHITE
    rect(slide, 0.35, y_r, 12.633, 0.5, rcolor)
    x = 0.4
    text_colors = [DARK_TEXT, MID_GREY, GREEN if ri < 2 else (RED_WARN if ri < 4 else TEAL), MID_GREY]
    for ci, (cell, w) in enumerate(zip(row, tir_cols)):
        textbox(slide, x, y_r+0.08, w-0.1, 0.34, cell, 12, text_colors[ci],
                align=PP_ALIGN.CENTER if ci > 0 else PP_ALIGN.LEFT,
                valign=MSO_ANCHOR.MIDDLE, bold=(ci==2))
        x += w

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 7 — AID Systems in Pregnancy
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "ADA 2026: Automated Insulin Delivery (AID) in Pregnancy",
           "Preferred insulin delivery system for T1DM — with formal pregnancy-specific guidance")
footer(slide)

# Main recommendation banner
rect(slide, 0.4, 1.25, 12.533, 0.7, NAVY)
textbox(slide, 0.5, 1.3, 12.333, 0.6,
        "AID systems are now the PREFERRED insulin delivery method for all people with T1DM  (ADA 2026, Rec 7.25a)",
        18, WHITE, bold=True, align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)

# Left column
rect(slide, 0.4, 2.1, 5.9, 4.7, RGBColor(0xE8,0xF0,0xFF))
textbox(slide, 0.55, 2.15, 5.6, 0.4, "What AID Does in Pregnancy", 15, NAVY, bold=True)
bullet_box(slide, 0.4, 2.55, 5.9, 3.8,
           ["Automatically adjusts basal insulin based on CGM readings",
            "Reduces time in hypoglycaemia (critical in 1st trimester)",
            "Reduces time in hyperglycaemia in 3rd trimester",
            "Reduces glycaemic variability — CV improves",
            "Improves maternal quality of life & sleep",
            "Consolidated into Section 15 (pregnancy) from Section 7 in 2026"],
           bullet_size=13)

# Right column
rect(slide, 6.7, 2.1, 6.233, 4.7, RGBColor(0xF0,0xF8,0xF0))
textbox(slide, 6.85, 2.15, 5.9, 0.4, "2026 Pregnancy-Specific Guidance", 15, GREEN, bold=True)
bullet_box(slide, 6.7, 2.55, 6.233, 3.8,
           ["Counsel patients on use of AID across all trimesters",
            "Guidance on switching: automated ↔ manual modes",
            "Manual mode during labour & delivery (intrapartum)",
            "Resume AID postpartum — insulin needs drop dramatically after delivery",
            "Open-source AID systems: ADA reaffirms support",
            "AID + CGM together: best outcomes — do not separate them"],
           bullet_size=13)

# Bottom note
rect(slide, 0.4, 6.88, 12.533, 0.45, RGBColor(0xFF,0xF8,0xE0))
textbox(slide, 0.55, 6.9, 12.3, 0.4,
        "Note: AID was previously discussed in BOTH Section 7 and Section 15 — ADA 2026 consolidated all pregnancy AID guidance exclusively to Section 15 for clarity.",
        11, GOLD, italic=True, wrap=True)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 8 — GLP-1 RAs: Preconception Guidance
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "ADA 2026: GLP-1 RAs — NEW Preconception Guidance",
           "Major new recommendation: discontinue GLP-1 RAs before attempting conception", bar_color=RED_WARN)
footer(slide)

# Warning banner
rect(slide, 0.4, 1.25, 12.533, 0.75, RED_WARN)
textbox(slide, 0.5, 1.28, 12.333, 0.69,
        "⚠  GLP-1 RAs (semaglutide, liraglutide) and dual GIP/GLP-1 RAs (tirzepatide) MUST be discontinued BEFORE conception",
        20, WHITE, bold=True, align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)

# Three columns
col_data = [
    ("Why Discontinue?", NAVY, [
        "GLP-1 RAs are contraindicated in pregnancy",
        "Animal studies show teratogenicity / embryotoxicity",
        "Human safety data in pregnancy insufficient",
        "Placental transfer unknown / possible",
        "Manufacturer labelling contraindicates use",
    ]),
    ("When to Discontinue?", TEAL, [
        "Discontinue BEFORE attempting conception",
        "Ensure preconception glycaemic goals are achieved AFTER stopping the GLP-1 RA",
        "Allow adequate washout period",
        "Switch to insulin if required to maintain glycaemic control",
        "Document contraception counselling",
    ]),
    ("What to Use Instead?", GREEN, [
        "Insulin — preferred agent for pgDM in pregnancy",
        "Metformin — acceptable alternative for GDM / T2DM",
        "Target HbA1c < 6% preconception",
        "Reassess after delivery: GLP-1 RA may be restarted postpartum",
        "Breastfeeding: safety of GLP-1 RAs not established",
    ]),
]
for i, (title, col, items) in enumerate(col_data):
    x_pos = 0.35 + i * 4.3
    rect(slide, x_pos, 2.1, 4.1, 4.6, RGBColor(0xF8,0xF8,0xFF) if col != GREEN else RGBColor(0xF0,0xF8,0xF0))
    textbox(slide, x_pos+0.1, 2.15, 3.9, 0.4, title, 15, col, bold=True)
    bullet_box(slide, x_pos, 2.55, 4.1, 3.8, items, bullet_size=13)

# T1DM note
rect(slide, 0.4, 6.78, 12.533, 0.5, RGBColor(0xFF,0xF5,0xE8))
textbox(slide, 0.55, 6.82, 12.3, 0.42,
        "NEW in ADA 2026: GLP-1 RAs now supported for adults with T1DM + obesity (BMI >30)  — but the STOP-BEFORE-PREGNANCY rule applies equally.",
        12, GOLD, bold=True, italic=False, wrap=True)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 9 — Insulin Management
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "Insulin Management in Diabetic Pregnancy",
           "ADA 2026: Updated guidance on insulin preparations | Preferred agent for pgDM & GDM pharmacotherapy")
footer(slide)

# Dosing table
rect(slide, 0.4, 1.25, 12.533, 0.45, NAVY)
textbox(slide, 0.5, 1.28, 12.3, 0.41, "INSULIN DOSE REQUIREMENTS BY TRIMESTER",
        14, WHITE, bold=True, align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)

trim_rows = [
    ("1st Trimester", "0.7–0.8 units/kg/day", "May DECREASE 9–16 wks in T1DM (hypoglycaemia risk!)"),
    ("2nd Trimester", "0.8–1.0 units/kg/day", "Progressive insulin resistance from placental hormones"),
    ("3rd Trimester", "0.9–1.2 units/kg/day", "Greatest increase 16–37 wks; plateau near term"),
    ("Postpartum", "Drops dramatically", "Placenta expelled → insulin resistance resolves abruptly"),
]
for ri, (trim, dose, note) in enumerate(trim_rows):
    y_r = 1.75 + ri * 0.65
    rcolor = RGBColor(0xF0,0xF5,0xFF) if ri % 2 == 0 else WHITE
    rect(slide, 0.4, y_r, 12.533, 0.6, rcolor)
    textbox(slide, 0.5, y_r+0.1, 2.5, 0.4, trim, 14, NAVY, bold=True, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, 3.1, y_r+0.1, 3.2, 0.4, dose, 15, TEAL, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, 6.4, y_r+0.1, 6.4, 0.4, note, 12, MID_GREY,
            valign=MSO_ANCHOR.MIDDLE, wrap=True)

# Insulin preparations
rect(slide, 0.4, 4.45, 6.0, 2.25, RGBColor(0xE8,0xF5,0xF8))
textbox(slide, 0.55, 4.5, 5.7, 0.35, "Acceptable Insulin Preparations in Pregnancy", 14, TEAL, bold=True)
bullet_box(slide, 0.4, 4.85, 6.0, 1.7,
           ["Basal-bolus regimen preferred (long-acting + rapid-acting)",
            "Rapid-acting: Aspart, Lispro (preferred — most data)",
            "Long-acting: Detemir or NPH (detemir has RCT data in pregnancy)",
            "Glargine U-100: off-label but growing evidence",
            "Insulin pump (CSII): continue if well-established pre-pregnancy"],
           bullet_size=12)

# Oral agents
rect(slide, 6.8, 4.45, 5.933, 2.25, RGBColor(0xFFF8E8))
textbox(slide, 6.95, 4.5, 5.7, 0.35, "Oral Agents — Role & Limitations", 14, GOLD, bold=True)
bullet_box(slide, 6.8, 4.85, 5.933, 1.7,
           ["Metformin: lower GWG, lower preeclampsia vs glyburide — but crosses placenta",
            "Glyburide: crosses placenta → higher neonatal hypoglycaemia — increasingly disfavoured",
            "Both only for GDM patients who decline/cannot reliably take insulin",
            "Unknown long-term offspring effects of metformin (↑ adiposity in some studies)"],
           bullet_size=12)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 10 — Blood Pressure & Complications
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "ADA 2026: Blood Pressure & Maternal Complications",
           "Rec 15.24 revised — BP threshold aligned with CHAP trial evidence")
footer(slide)

# BP update
rect(slide, 0.4, 1.25, 12.533, 0.85, RGBColor(0xE8,0xF0,0xFF))
rect(slide, 0.4, 1.25, 0.15, 0.85, NAVY)
textbox(slide, 0.65, 1.3, 12.1, 0.75,
        "UPDATED (ADA 2026 Rec 15.24):  Initiate or titrate antihypertensive therapy at BP ≥ 140/90 mmHg\n"
        "Aligned with CHAP trial (N Engl J Med 2022) — treatment at this threshold reduces adverse outcomes without increasing IUGR",
        14, NAVY, bold=False, wrap=True, valign=MSO_ANCHOR.MIDDLE)

# Complications table
textbox(slide, 0.4, 2.25, 12.533, 0.35, "Maternal Complications of Pregestational DM",
        14, NAVY, bold=True)

comp_data = [
    ("Hypertension", "OR = 14.2", RED_WARN),
    ("Preeclampsia", "OR = 3.4", RED_WARN),
    ("Cesarean delivery", "OR = 11.3", GOLD),
    ("Preterm birth", "OR = 4.4", GOLD),
    ("Maternal mortality", "~60/100,000", MID_GREY),
]
for i, (comp, stat, col) in enumerate(comp_data):
    x_pos = 0.4 + i * 2.5
    rect(slide, x_pos, 2.65, 2.4, 0.9, col)
    textbox(slide, x_pos+0.05, 2.68, 2.3, 0.45, comp, 12, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, x_pos+0.05, 3.1, 2.3, 0.4, stat, 16, WHITE, bold=True,
            align=PP_ALIGN.CENTER)

# Ophthalmology
rect(slide, 0.4, 3.7, 5.9, 3.0, RGBColor(0xF0,0xF5,0xFF))
textbox(slide, 0.55, 3.75, 5.6, 0.35, "Retinopathy Monitoring in Pregnancy", 14, NAVY, bold=True)
bullet_box(slide, 0.4, 4.1, 5.9, 2.3,
           ["Screen BEFORE conception or at 1st prenatal visit",
            "No retinopathy / minimal NPDR → 1st & 3rd trimester",
            "Mild-moderate NPDR → every trimester (3×)",
            "High-risk NPDR / PDR → monthly",
            "GDM → no ophthalmic screening required",
            "PDR: treat with PRP; anti-VEGF avoided in pregnancy"],
           bullet_size=12)

# Nephropathy
rect(slide, 6.7, 3.7, 6.233, 3.0, RGBColor(0xF0,0xF8,0xF0))
textbox(slide, 6.85, 3.75, 5.9, 0.35, "Nephropathy & Other Complications", 14, GREEN, bold=True)
bullet_box(slide, 6.7, 4.1, 6.233, 2.3,
           ["Baseline 24-hr urine protein / PCR at booking",
            "Proteinuria often worsens transiently — monitor each trimester",
            "Pregnancy does not permanently accelerate nephropathy in most",
            "Neonatal risks: macrosomia, neonatal hypoglycaemia, RDS, congenital anomalies, shoulder dystocia",
            "Congenital anomalies linked to poor control at organogenesis (wks 5–8)"],
           bullet_size=12)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 11 — GDM: Step-by-Step Management
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "GDM: Updated Step-by-Step Management Algorithm",
           "Medical Nutrition Therapy → Exercise → SMBG/CGM → Pharmacotherapy")
footer(slide)

steps = [
    ("Step 1\nNutrition", NAVY,
     "Medical Nutrition Therapy (MNT)\n• Carbohydrate-controlled (not eliminated): 33–40% carbs\n• ~1800–2200 kcal/day distributed across 3 meals + 2–3 snacks\n• Complex carbs; avoid refined sugars; adequate fibre"),
    ("Step 2\nExercise", TEAL,
     "Physical Activity\n• Brisk walking 20–30 min, 3× per week minimum\n• Reduces postprandial glucose peaks\n• 2026 IPD meta-analysis: exercise + diet most effective GDM prevention strategy"),
    ("Step 3\nMonitoring", GREEN,
     "SMBG + CGM (NEW 2026)\n• Fasting + 1-hr post each meal (4 readings/day minimum)\n• CGM now recommended for GDM on insulin (and discussed for diet-only)\n• TIRp target: >70% time in 63–140 mg/dL"),
    ("Step 4\nPharmaco-\ntherapy", GOLD,
     "If targets not met with Step 1–3:\n• Insulin — preferred (does not cross placenta)\n• Metformin — alternative (lower GWG, lower preeclampsia vs glyburide)\n• Glyburide — increasingly disfavoured (placental transfer → neonatal hypoglycaemia)"),
]

for i, (step, col, detail) in enumerate(steps):
    x_pos = 0.3 + i * 3.2
    rect(slide, x_pos, 1.3, 1.0, 1.5, col)
    textbox(slide, x_pos+0.02, 1.35, 0.96, 1.4, step, 13, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    rect(slide, x_pos+1.05, 1.3, 2.1, 1.5, RGBColor(0xF5,0xF9,0xFF))
    textbox(slide, x_pos+1.1, 1.35, 2.0, 1.4, detail, 11, DARK_TEXT,
            wrap=True, valign=MSO_ANCHOR.TOP)

# Delivery timing
rect(slide, 0.3, 3.0, 12.733, 0.4, NAVY)
textbox(slide, 0.4, 3.02, 12.5, 0.36, "DELIVERY TIMING & ROUTE", 14, WHITE, bold=True,
        align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)

deliv_data = [
    ("GDM — diet controlled", "Deliver by 39 weeks", "Vaginal delivery if no macrosomia"),
    ("GDM — on medication", "Induce at 39 weeks", "Consider induction in early term (37–39 wks)"),
    ("pgDM — well controlled", "Induce 37–39 weeks", "C-section if EFW ≥ 4,500 g (shoulder dystocia risk)"),
    ("Macrosomia EFW ≥4,500g", "Cesarean delivery", "Regardless of diabetes type"),
]
for ri, (scenario, timing, note) in enumerate(deliv_data):
    y_r = 3.45 + ri * 0.72
    rcolor = RGBColor(0xF0,0xF5,0xFF) if ri % 2 == 0 else WHITE
    rect(slide, 0.3, y_r, 12.733, 0.67, rcolor)
    textbox(slide, 0.4, y_r+0.12, 4.2, 0.43, scenario, 13, NAVY, bold=True, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, 4.7, y_r+0.12, 3.5, 0.43, timing, 14, TEAL, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    textbox(slide, 8.3, y_r+0.12, 4.6, 0.43, note, 12, MID_GREY, valign=MSO_ANCHOR.MIDDLE, wrap=True)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 12 — Postpartum & Long-Term Follow-Up
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "Postpartum Management & Long-Term Follow-Up",
           "Critical window — GDM = 7–10× lifetime T2DM risk")
footer(slide)

# Timeline
milestones = [
    ("Delivery", "• Insulin dose drops dramatically\n• GDM usually resolves\n• Resume pre-preg insulin doses (pgDM)\n• Begin breastfeeding counselling", NAVY),
    ("4–12 Weeks", "• 75-g 2-hr OGTT for ALL GDM women\n• Preferred over HbA1c (still falsely low)\n• Screen for T2DM / prediabetes / normal\n• Restart GLP-1 RA if applicable", TEAL),
    ("Annual\nFollow-Up", "• Fasting glucose or HbA1c annually\n• Lifestyle counselling: weight loss, exercise\n• Metformin in high-risk women\n• CV risk assessment", GREEN),
    ("Future\nPregnancy", "• Preconception HbA1c < 6%\n• Switch to insulin before conception\n• Discontinue GLP-1 RA before conception\n• GDM recurs in ~50% of subsequent pregnancies", GOLD),
]
for i, (time, detail, col) in enumerate(milestones):
    x_pos = 0.3 + i * 3.2
    rect(slide, x_pos, 1.25, 3.0, 0.6, col)
    textbox(slide, x_pos+0.05, 1.28, 2.9, 0.54, time, 15, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    rect(slide, x_pos, 1.85, 3.0, 3.0, RGBColor(0xF5,0xF9,0xFF))
    textbox(slide, x_pos+0.1, 1.9, 2.8, 2.9, detail, 12, DARK_TEXT,
            wrap=True, valign=MSO_ANCHOR.TOP)

# Risk reduction
rect(slide, 0.3, 5.0, 12.733, 1.55, RGBColor(0xF0,0xF8,0xF0))
textbox(slide, 0.45, 5.05, 12.4, 0.35, "T2DM Risk Reduction Strategies After GDM", 14, GREEN, bold=True)
strategies = [
    "GDM = 7–10× increase in T2DM risk  |  10% convert within 5 years of delivery",
    "Weight loss: most impactful intervention — even 5–7% weight reduction significantly lowers risk",
    "Exercise: ≥150 min/week moderate intensity  |  Metformin: reduces T2DM risk ~35% in high-risk GDM women",
    "Breastfeeding: associated with improved maternal glucose tolerance and reduced T2DM risk",
]
y_s = 5.42
for s in strategies:
    textbox(slide, 0.5, y_s, 12.4, 0.26, "• " + s, 12, DARK_TEXT, wrap=True)
    y_s += 0.27

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 13 — Summary Comparison Table
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "Summary: What Changed — Old vs. New at a Glance",
           "Quick reference for practice updates")
footer(slide)

# Table
rect(slide, 0.3, 1.25, 12.733, 0.5, NAVY)
col_headers = ["Clinical Topic", "Old Guidance", "2024–2026 Update", "Source"]
col_widths   = [3.0, 3.2, 4.5, 1.833]
x = 0.4
for h, w in zip(col_headers, col_widths):
    textbox(slide, x, 1.28, w-0.1, 0.44, h, 13, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    x += w

table_rows = [
    ("1st-trimester screening", "High-risk only", "Universal for all pregnant women", "ACOG 2024"),
    ("CGM in T2DM / GDM", "T1DM focus only", "Expanded to T2DM & GDM", "ADA 2026"),
    ("AID systems in pregnancy", "Limited guidance", "Preferred for T1DM; mode-switching counselling", "ADA 2026"),
    ("GLP-1 RAs before conception", "Not addressed", "Must discontinue before attempting conception", "ADA 2026"),
    ("BP threshold for treatment", "Variable / conservative", "≥ 140/90 mmHg — standardised", "ADA 2026"),
    ("CGM TIR targets", "Not specified", "TIRp > 70% in 63–140 mg/dL range", "ADA 2026"),
    ("Early GDM (< 24 wks)", "Section 2 (classification)", "Section 15 with updated evidence", "ADA 2026"),
    ("GDM pharmacotherapy", "Metformin / glyburide mentioned", "Glyburide increasingly disfavoured; metformin caution", "ADA 2026"),
]
for ri, row in enumerate(table_rows):
    y_r = 1.8 + ri * 0.62
    rcolor = RGBColor(0xF0,0xF5,0xFF) if ri % 2 == 0 else WHITE
    rect(slide, 0.3, y_r, 12.733, 0.58, rcolor)
    x = 0.4
    tcols = [NAVY, MID_GREY, TEAL, GOLD]
    for ci, (cell, w) in enumerate(zip(row, col_widths)):
        textbox(slide, x, y_r+0.08, w-0.1, 0.42, cell, 12, tcols[ci],
                bold=(ci == 0), wrap=True, valign=MSO_ANCHOR.MIDDLE,
                align=PP_ALIGN.CENTER if ci > 0 else PP_ALIGN.LEFT)
        x += w

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 14 — CME Questions / Post-Test
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide)
header_bar(slide, "CME Post-Test Questions", "Answer all 3 questions to claim credit")
footer(slide)

questions = [
    ("Q1", "According to ACOG 2024, when should ALL pregnant women be screened for undiagnosed T2DM?",
     ["A) 24–28 weeks (GDM screening window)",
      "B) At the first prenatal visit  ✓ CORRECT",
      "C) Only if BMI > 30",
      "D) Third trimester if glucose is elevated"]),
    ("Q2", "Which CGM metric is the primary target in T1DM pregnancy per ADA 2026?",
     ["A) HbA1c < 6.5%",
      "B) Time In Range (63–140 mg/dL) > 70%  ✓ CORRECT",
      "C) Fasting glucose < 126 mg/dL",
      "D) Postprandial peak < 200 mg/dL"]),
    ("Q3", "A patient with T2DM on semaglutide is planning pregnancy. What is the correct action?",
     ["A) Continue semaglutide until positive pregnancy test",
      "B) Switch to glyburide",
      "C) Discontinue GLP-1 RA before conception; achieve glycaemic goals first; switch to insulin  ✓ CORRECT",
      "D) Reduce semaglutide dose to lowest available"]),
]
for qi, (num, question, options) in enumerate(questions):
    y_q = 1.4 + qi * 1.85
    rect(slide, 0.3, y_q, 0.7, 1.65, NAVY)
    textbox(slide, 0.32, y_q+0.5, 0.66, 0.65, num, 18, WHITE, bold=True,
            align=PP_ALIGN.CENTER, valign=MSO_ANCHOR.MIDDLE)
    rect(slide, 1.05, y_q, 11.978, 1.65, RGBColor(0xF8,0xF9,0xFF))
    textbox(slide, 1.15, y_q+0.05, 11.7, 0.42, question, 14, NAVY, bold=True, wrap=True)
    opt_text = "     ".join(options)
    textbox(slide, 1.15, y_q+0.5, 11.7, 1.1, opt_text, 12, DARK_TEXT, wrap=True)

# ════════════════════════════════════════════════════════════════════════════
# SLIDE 15 — References & Credits
# ════════════════════════════════════════════════════════════════════════════
slide = prs.slides.add_slide(blank)
bg(slide, NAVY)
rect(slide, 0, 6.8, 13.333, 0.7, TEAL)

textbox(slide, 0.5, 0.2, 12.333, 0.6, "References & Acknowledgements",
        26, WHITE, bold=True, align=PP_ALIGN.CENTER)

refs = [
    "1.  American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S321–S338. doi:10.2337/dc26-S015",
    "2.  American Diabetes Association. Summary of Revisions: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). PMC12690167",
    "3.  ACOG Clinical Practice Update: Screening for Gestational and Pregestational Diabetes in Pregnancy and Postpartum. Obstet Gynecol. 2024;144(1):e20–e23. doi:10.1097/AOG.0000000000005612",
    "4.  Benhalima K, Durnwald C, Sweeting A, et al. CGM and AID in pregnant women with T1, T2, or GDM: international consensus statement. Lancet Diabetes Endocrinol. 2026;14:157–177.",
    "5.  Fatima K, Siddiqi AK, Shakil S. Safety and efficacy of insulin detemir vs NPH in pregnant women: systematic review and meta-analysis. Minerva Obstet Gynecol. 2024 Dec. PMID 37877940",
    "6.  Allotey J, et al. Effects of physical activity and diet in pregnancy to prevent GDM: IPD meta-analysis. Health Technol Assess. 2026 May. PMID 42117518",
    "7.  Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice, 9th Ed. Chapters 59 & 60.",
    "8.  Harrison's Principles of Internal Medicine, 22nd Ed. (2025). Diabetes Mellitus in Pregnancy.",
]
y_r = 1.0
for ref in refs:
    textbox(slide, 0.5, y_r, 12.333, 0.45, ref, 11, RGBColor(0xCC,0xDD,0xEE), wrap=True)
    y_r += 0.48

textbox(slide, 0.5, 6.82, 12.333, 0.35,
        "This CME presentation was prepared for educational purposes.  Content is based on published guidelines as of July 2026.  Always apply clinical judgment.",
        10, WHITE, align=PP_ALIGN.CENTER)

# ── Save ────────────────────────────────────────────────────────────────────
from io import BytesIO
buf = BytesIO()
prs.save(buf)
with open("/tmp/workspace/cme-diabetes-pregnancy/ADA_ACOG_2026_DM_Pregnancy_CME.pptx", "wb") as f:
    f.write(buf.getvalue())

print("DONE — file saved successfully")

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

I have pateint with retinopathy when should idelivery and mode of delivery

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.